Format

Send to

Choose Destination
Dement Neurocogn Disord. 2019 Jun;18(2):33-46. doi: 10.12779/dnd.2019.18.2.33. Epub 2019 Jun 24.

A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation.

Author information

1
Department of Neurology, Hanyang University College of Medicine, Seoul, Korea.
2
Department of Neurology, Konkuk University School of Medicine, Seoul, Korea.
3
Department of Laboratory Medicine, Hanyang University College of Medicine, Seoul, Korea.
4
Stem Cell Neuroplasticity Research Group, Kyungpook National University, Daegu, Korea.
5
Department of Physiology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, Korea.
6
Department of Laboratory Animal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu, Korea.

Abstract

Alzheimer's disease (AD), the most common form of dementia, has emerged as a major global public health challenge. However, the complexity of AD in its biological, genetic, and clinical aspects has hindered the development of effective therapeutic agents. Research plans that integrate new drug discoveries are urgently needed, including those based on novel and reliable biomarkers that reflect not only clinical phenotype, but also genetic and neuroimaging information. Therapeutic strategies such as stratification (i.e., subgrouping of patients having similar clinical characteristics or genetic background) and personalized medicine could be set as new directions for developing effective drugs for AD. In this review, we describe a therapeutic strategy that is based on immune-inflammation modulation for a subgroup of AD and related dementias, arguing that the use of stratification and personalized medicine is a promising way to achieve targeted medicine. The Korean AD Research Platform Initiative based on Immune-Inflammatory biomarkers (K-ARPI) has recently launched a strategy to develop novel biomarkers to identify a subpopulation of patients with AD and to develop new drug candidates for delaying the progression of AD by modulating toxic immune inflammatory response. Sphingosine kinase 1 (SphK1) and its metabolites, triggering receptor expressed on myeloid cells-2 (TREM2) related signals, and actin motility related proteins including Nck-associated protein 1 (Nap1) were selected as promising targets to modulate neuroinflammation. Their roles in stratification and personalized medicine will be discussed.

KEYWORDS:

Alzheimer's Disease; Biomarkers; Inflammation; Personalized Medicine

Conflict of interest statement

Conflict of Interest: The authors have no financial conflicts of interest.

Publication type

Publication type

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center